Table 3.

Summary of the state-of-the-art of CD34+ cell therapy and it’s clinical trials for the cardiovascular diseases (Prasad et al., 2020).

Authors	Country	Sample size	Disease	Design	Delivery	Follow-up	Results
Quyyumi et al;	USA	168	STEMI	Randomized double-blinded	Intra-coronary	6 months	Reduced infarct size, reduced MACE, improved ejection fraction
Losordo et al;	USA	167	Refractory angina	Randomized double-blinded	Intra-myocardial	1 year	An important decline in the angina frequency. Improvement in the work-out tolerance.
Wang et al;	China	112	Refractory angina	Randomized double blinded	Intra-coronary	6 months	Significant reduction in angina frequency and enhancement in myocardial perfusion.
Lee et al;	Taiwan	38	Refractory angina	Randomized double-blinded	Intra-coronary	1 year	Decreased angina, improved ejection fraction.
Vrtovec et al;	Slovenia	110	Dilated cardiomyopathy	Randomized double-blinded	Intra-coronary	5 years	Increased LVEF, Increased 6MWD and decrease in NT pro-BNP, decreased mortality.
Bervar et al;	Slovenia	38	Dilated cardiomyopathy	Randomized double-blinded	Trans-endocardia	1 year	Increased 6MWD, decrease in NT-pro BNP, and significant improvement in diastolic parameters
Lezaic et al;	Slovenia	21	Dilated cardiomyopathy	Randomized double-blinded	Intra-coronary	6 months	Improved rest myocardial perfusion, LVEF, 6-minute walking distance.